Pharmaceutical Shanghai Yingli Pharmaceutical announced that linperlisib, trade name因他瑞®, a novel phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, has been approved by the National Medical Products Administration (NMPA) of China for the treatment of relapsed/refractory follicular lymphoma (R/R FL) in patients who have received two or more prior systemic therapies. 9 November 2022